Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Molecular diagnostics group Yourgene Health said its revenue in the first half almost doubled, in line with its expectations.
Revenue for the six months through September rose 98% to £7.8m, up from £3.9m on-year.
International revenues continued to show strong momentum, the company said, with the Elucigene Diagnostics business, acquired on 26 April, contributing primarily to UK and European sales growth.
Organic growth, excluding contributions from the Elucigene acquisition, was 56%.
Cash and cash equivalents at 30 September were £4.1m.